Banks face stringent new rules on how they calculate capital requirements, yet until now have lacked sufficient data to underpin how they model this. Steven Holland reveals how a new solution is about to make life easier. The Global Financial Crisis marked a turning point for banking regulation. As financial watchdogs across the world sought to eliminate a repeat of the 2008 crash, a range of new regulations were imposed which were designed to shore up institutions’ capital reserves and provide greater financial security.
Among those was the Fundamental Review of the Trading Book (FRTB), designed by the Basel Committee on Banking Supervision (BCBS) as an international standard laying out the rules governing the amount of capital banks must hold against market risk.
Included in the Basel III regulations, and subject to reforms due to come into force in 2024 /2025 depending on the financial jurisdiction, FTRB imposes more stringent rules for banks that use proprietary models for calculating capital and ensures they capture tail risk. It also reinforces the boundary between trading and banking books. This will make it easier to compare risk-based capital ratios across banks, and is intended to restore confidence in those ratios and the soundness of the sector overall.
Banks using the internal model approach (IMA) must employ the expected shortfall measure to calculate capital, as well as applying capital add-ons for risk factors that lack sufficient data for modelling. These are known as non-modellable risk factors (NMRF). Increasingly banks, especially large institutions, are looking to use IMA rather than relying on the solvency assessment imposed by regulators, since these may mean they can hold lower capital reserves.Yet the move to IMA is far from straightforward and, so far, we have seen a relatively low take up.
Data challenges
The introduction of FRTB will be a game changer for capital market trading businesses and has reinforced the need for banks to have access to high quality real observable trade and order data to accurately mark their OTC positions. Yet there are several challenges banks must overcome if they are to comply with the new regulations: Firstly, it can be problematic for banks to gather the requisite data to assess whether a Standardized Approach (SA) or IMA would be better for their institution. Secondly, banks often struggle to harmonise and align data across different sources and, in some areas, this may necessitate a complete reengineering of their data processes. There are also challenges in finding the relevant data for the risk factor eligibility test (RFET) due to the quality and quantity of data required across all asset classes and types, including linear and non-linear products. The combination of these factors makes it difficult for banks to justify investing in a new data infrastructure to support IMA if they cannot be sure it leads to lower capital requirements.
A new solution
However, breakthroughs in the market are making life easier for banks to move to proprietary approaches to capital modelling. As an operator of multiple venues across many regions and asset classes, TPICAP and Parameta solutions offer clients a golden source of observational data to help them run their RFET and the expected shortfall tests that are necessary to assess how to model their risk factors. This data sits mainly in the OTC and non-linear sphere, where market data is scarce. The solution consists of a daily/monthly set of files containing price observations covering both trade data and ’committed quote’ data. This approach brings together observational data from all our venues across the globe, covering EMEA, APAC, and the Americas. Comprehensive asset class coverage includes credit, equities, FX, fixed income, commodities, and derivatives thereof.
Time to review
FRTB presents an updated Standardized Approach while also revising the framework for the Internal Model Approach. Both methods present their own challenges, and to effectively implement FRTB, banks must examine and enhance their risk architecture and governance processes. They will also need to think about the way in which they obtain and use their reference and market data, if they are to satisfy some of the more data-intense elements of FRTB. The UK has pushed back its deadline for implementing Basel III, giving banks more time to consider the benefits of moving to IMA. The US is likely to follow suit and the EU may also align, which would provide a consistent approach across the world. Banks can use this extra time to look into ways to enhance their data gathering and analysis, enabling them to better understand the possibilities of moving to IMA. Parameta Solutions has exclusive access to trade and order data on a wide range of OTC products, making us ideally placed to provide the requisite market data for clients on their compliance journeys.
© 2024 ICAP Information Services Limited (“IISL”). This communication is provided by ICAP Information Services Limited or a member of its group (“Parameta”) and all information contained in or attached hereto (the “Information”) is for information purposes only and is confidential. Access to the Information by anyone other than the intended recipient is unauthorised without Parameta’s prior written approval. The Information may not be not used or disclosed for any purpose without Parameta’s prior written approval, including without limitation, storing, copying, distributing, licensing, selling or displaying the Information, using the Information in an application or to create derived data of any kind, co-mingling the Information with any other data or using the data for any unlawful purpose of for any purpose that would cause it to become a benchmark under any law, regulation or guidance.
The Information is not, and should not be construed as, a live price, an offer, bid, recommendation or solicitation in relation to any financial instrument or investment or to participate in any particular trading strategy or constituting financial or investment advice or a financial promotion. The Information is not to be relied upon for any purpose whatsoever and is provided “as is” without warranty of any kind, either expressly or by implication, including without limitation as to completeness, timeliness, accuracy, continuity, merchantability or fitness for any particular purpose. All representations and warranties are expressly disclaimed, to the fullest extent possible under applicable law. In no circumstances will Parameta be liable for any indirect or direct loss, or consequential loss or damages including without limitation, loss of business or profits arising from the use of, any inability to use, or any inaccuracy in the Information. Parameta may suspend, withdraw or modify or change the terms of the provision of the Information at any time in its sole discretion, without notice.
All rights, including without limitation intellectual property rights, in and to the Information are, and shall remain, the property of IISL or its licensors. Use of, access to or delivery of Parameta’s products and/or services requires a prior written licence from Parameta or its relevant affiliates. The terms of this disclaimer are governed by the laws of England and Wales.
